July 2008.indd Assessment of the Relationship of Hepatic Enzymes with Obesity and Insulin Resistance in Adults in Saudi Arabia Ali Ibrahim Al-Sultan Department of Internal Medicine, College of Medicine in Al-Ahssa, King Faisal University, Kingdom of Saudi Arabia Email: dean-medicinehassa@kfu.edu.sa SULTAN QABOOS UNIVERSITY MEDICAL JOURNAL JULY 2008, VOLUME 8, ISSUE 2, P. 185-192 SULTAN QABOOS UNIVERSITY© SUBMITTED - 1ST JANUARY 2008 ACCEPTED - 15TH APRIL 2008 C L I N I C A L A N D B A S I C R E S E A R C H عند األنسولني ومقاومة والسمنة الكبدية األنزميات بني العالقة تقييم السعودية اململكة العربية في البالغني األفراد السلطان علي في البالغني األفراد عند األنسولني ومقاومة بالسمنة لأللبومني واملستوى املصلي الكبدية اإلنزميات عالقة ــة لتقييم الدراس أجريت امللخص: الهدف: األنثروبومترية املقاسات أخذ مت . بدين 68 غير و 68 بدينا من مكونه ، بالغ 136 سعودي ل دراسة مقارنة الطريقة: هذه السعودية. العربية اململكة النتائج: تقييم االستتباب. بنموذج األنسولني مقاومة وحتديد الدهون ــتوى ومس ــولني واألنس ، الدم وجلوكوز واأللبومني ، األنزميات الكبدية ــتوى ومس ، وحتديد ــولني واألنس إفطار) بدون – الصيام (بعد واجللوكوز ــة القلوي ــفاتيز الفوس إنزمي غلومتيل و غاما بيبتايد ناقالت ــتويات مس أن ــة الدراس ــرت أظه ارتبطت . (p<0.0001 و ,p<0.001, p<0.004, p<0.005, p<0.0001) ــني البدين ــد ــة عن عالي ــتتباب االس تقييم بنموذج ــولني مقاومة األنس مقاومة (حتديد ــولني األنس مقاومة وصمات مع الورك) اخلصر إلى محيط ــبة ونس ــم اجلس كتلة ــر (مؤش االنثروبومترية ــات باملقاس الكبدية األنزميات األقوى. هو غلومتيل غاما بيبتايد ناقالت ارتباط أن بينت فالدراسة ومع ذلك . الصيام) بعد ما جلوكوز واألنسولني و االستتباب تقييم بنموذج األنسولني تقييم مقاومة األنسولني بنموذج وحتديد اجلسم ومؤشر كتلة بني مستوى األلبومني اإلحصائية الناحية من معتدا ــيا عكس ارتباطا ــة الدراس أظهرت غاما بيبتايد ناقالت مستوى وخصوصا املعتلة الكبد وظائف اخلالصة: إن التوالي. على (p<0.01و ,p<0.01, p<0.05) واألنســــــولني االستتباب قد غلومتيل ناقالت بيبتايد غاما مستوى إن واألنســــــولني. االستتباب تقييم ومقاومة األنسولني بنموذج بالسمنة ارتباطه في هو األقوى غلومتيل هذه الكحول مقيد. استهالك حيث السعوديني البالغني عند األنسولني ومقاومة للسمنة املصاحبة املرضية الكبدية التغيرات على داللة أكثر يكون . في السمنة األلبومني أيض تغير احتمال تظهر النتائج العربية السعودية. اململكة املصل ، ألبومني ، األمني ناقالت أنزميات مقاومة األنسولني ، ، الكلمات: السمنة مفتاح ABSTRACT Objectives: This study was conducted to assess the relationship of hepatic enzymes and serum albumin to obesity and insulin resistance in adults in Saudi Arabia. Methods: A comparative study of 36 Saudi adults, comprising of 68 obese and 68 non- obese was conducted. Anthropometric measurements, hepatic enzymes, serum albumin, blood glucose, serum insulin, lipid profile, and homeostasis model assessment of insulin resistance (HOMA IR) were measured. Results: The study showed significantly higher levels of gamma glutamyl transpeptidase (GGT), alkaline phosphatase, fasting glucose, serum insulin, and HOMA IR p < 0.00, <0.004 < 0.005, <0.000, <0.000, among obese subjects. Hepatic enzymes correlated with both anthropometric measures (body mass index (BMI), and waist to hip ratio) and markers of insulin resistance (HOMA IR, insulin, and fasting glucose). However, the study found that GGT had the strongest associations. Significant inverse correlation was found between serum albumin and BMI, HOMA IR, and serum insulin, p< 0.0, <0.05, <0.0, respectively. Conclusion: Deranged liver functions, especially GGT, had the strongest correla- tions with obesity and HOMA IR. GGT might be a better marker of hepatic pathology associated with obesity and insulin resistance in Saudi adults with restricted alcohol intake. The results also propose that albumin metabolism might be altered in obesity. Keywords: Obesity; Insulin resistance; Transaminases; Serum albumin; Saudi Arabia. Advances in Knowledge • Gamma glutamyl transpeptidase might be a better marker of hepatic pathology associated with obesity and insulin resistance in Saudi adults with restricted alcohol intake. A L I I B R A H I M A L -S U LTA N 186 OBESITY IS A MAJOR HEALTH PROBLEM. Non-alcoholic fatty liver disease is a hepat-ic dysfunction frequently associated with obesity,1, 2 and the fatty liver changes correlate with the severity of obesity.3, 4 The literature is well documented for the association of the levels of hepatic enzymes and obesity,5-11 and for measured percentage body fat.12-14 This association with obesity had been shown for non- alcoholic fatty liver disease either diagnosed by ultra- sound or liver biopsy.1, 4, 15, 16 The relationship of hepatic enzymes as markers of non-alcoholic fatty liver disease and insulin resistance was appreciated by the predic- tion of metabolic syndrome and Type 2 diabetes mel- litus. Alanine aminotransferase (ALT) predicts meta- bolic syndrome or correlates with its components,8, 17, 18 as well gamma glutamyl transpeptidase (GGT),6 or both.2 ALT predicts diabetes mellitus,8, 9 and simi- lar observations are attributed to GGT,19-23 or both. 10 ALT and GGT correlates with surrogates of insulin resistance,2, 7, 10, 16, 24 and with directly measured insu- lin resistance.9, 12 GGT is a sensitive marker for liver damage, but less specific than other hepatic enzymes. Alcohol intake is prohibited by religion and enforced by law in Saudi Arabia. The pattern of these enzymes in relation to obesity and insulin resistance is not well documented in such an environment. Glycated albu- min is associated negatively with obesity in non-dia- betic children.25 It has been reported that serum albu- min is low in obese individuals even with normal liver histology.3 The aim of the study was to assess the relationship of hepatic enzymes and serum albumin to obesity and insulin resistance in adult Saudi individuals. M E T H O D S The study was conducted over a one year period (2004 - 2005) at the Departments of Internal Medicine in the Colleges of Medicine in Al-Ahsa and Dammam, at King Faisal University, Kingdom of Saudi Arabia. A total of 136 volunteer subjects were included. They were non-diabetic with normal blood urea nitrogen and serum creatinine, and had no microalbuminuria (urine albumin to creatinine ratio less than 0.03 mg/ mg in overnight early morning sample). They were stratified into obese and non-obese groups according to international criteria. Serum liver chemistry, fast- ing glucose, insulin and lipid profile were measured. The scores for homeostasis model assessment of in- sulin resistance (HOMA IR) were calculated with the formula: fasting serum insulin (µU/ml) X fasting se- rum glucose (mmol/l) / 22.5 as described by Matthews and his colleagues.26 There were 68 (34 males and 34 females) non- obese subjects with normal body mass index (BMI) less than 25, and 68 (34 males and 34 females) obese subjects with BMI equal or more than 30. Non-obese subjects had normal blood pressure <18.66/11.99 KPa (<140 / 90 mmHg), normal oral glucose tolerance and within normal liver function tests. Obese subjects had normal liver chemistry except 8 subjects (11.7%) with only alanine aminotransferase (ALT) increased, which was less than 2 times the normal upper limit. There were nine subjects (13.2%) with blood pressure > 18.66/11.99 KPa (> 140 / 90 mmHg), eight subjects (11.7%) with impaired fasting glucose, two subjects (2.9%) with impaired glucose tolerance, and the rest had normal oral glucose tolerance. Subjects were included with following criteria: age between 18 - 65 years, Saudi nationals, normal blood urea nitrogen and serum creatinine, normal total bi- lirubin and no microalbuminuria (urine albumin to creatinine ratio less than 0.03 mg/mg in overnight early morning sample). Subjects were excluded if they were diabetic, had abnormal hepatitis B or C serol- ogy, known liver disease, alcohol intake, medications, and current acute or chronic illness. The study was approved by the Research and Ethical Committee of King Faisal University and consent was taken from study subjects. Height and weight was measured using Detecto scale to the nearest 0.5 cm and 0.1 kg respectively. Body mass index (BMI) was defined as the weight in kilograms divided by the square of the height in me- ters. Waist circumference was measured at the high- est point of the iliac crest and hip circumference meas- ured at the maximum circumference of the buttocks. Normal waist to hip ratio was < 0.9 for men and < 0.85 for women. A mean of two measurements of blood Application to Patient Care • In patients with non-alcoholic fatty liver disease, gamma glutamyl transpeptidase has a stronger positive cor- relation to obesity than other hepatic enzymes in Saudi adults. A S S E S S M E N T O F T H E R E L AT I O N S H I P B E T W E E N H E PAT I C E N Z Y M E S W I T H O B E S I T Y A N D I N S U L I N R E S I S TA N C E I N A D U LT S I N S AU D I A R A B I A 187 pressure at lying and sitting positions was calculated. Serum glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL)-cholesterol, blood urea nitrogen (BUN), creatinine, serum albumin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferas (AST), gamma glutamyl transpepti- dase (GGT), and alkaline phosphatase (ALP) were measured by the Dimension RXL analyzer (Dade Be- hring). Serum insulin was measured by a microenzyme immunoassay using IMX analyzer (Abbott Diagnos- tics). Urine for micro-albumin was measured by a par- ticle-enhanced turbidimetric inhibition immunoassay using the ACA Star analyzer by Dade Behring. A 75 g oral glucose tolerance test and early morn- ing urine sample for microalbuminuria were carried out for all subjects. Venous blood samples were ob- tained in the morning after 12 hours overnight fast. Serum specimens were stored at - 70c until analysis. Normal ranges for liver chemistries in our hospital were total bilirubin 1.7 – 17.1 µmol/l, total protein 60 - 80 g/l, albumin 35 - 48 g/l, ALT 20 - 65 U/l, AST 7 - 41 U/l, GGT 5 - 85 U/l, and ALP 50 -140 U/l. A quality control program was carried out regular- ly in our laboratories including system check, quality controls, and calibrations/verifications according to system manufacturers’ instructions and recommenda- tions. The sample size is based on assuming the worse ac- ceptable probability of the adverse outcome: ‘elevated hepatic transaminases’ to be 20% in obese and 2% in non-obese adult individuals with a type II error of 20% to achieve statistical significance at a confidence level of 95% and power of 80%. The least total number of obese and non-obese subjects would be 56 each. Statistical analysis was performed using SPSS (Sta- tistical Package for the Social Sciences) statistical soft- ware version 12.0. Student t - test, and Mann-Whit- ney test were carried out according to the results of Levene’s test of homogeneity for equal variances as appropriate. Pearson correlation coefficients were Table 1: Clinical and biochemical characteristics of all 136 study subjects. Variable Non-Obese Obese P value Number of subjects 68 68 Males (%) 34 (50%) 34 (50%) Age (years) 24.6 + 3.7 28.8 + 6.9 <0.0001 Body mass index 22.7 + 2.2 36.5 + 7.3 <0.0001 Waist to hip ratio 0.796 + 0.094 0.885 + 0.083 <0.0001 Systolic BP (KPa) 15.13 + 1.73 (113.5 +13.0 mmHg) 16.17 + 1.97 (121.3 + 14.8 mmHg) <0.007 Diastolic BP (KPa) 9.53 + 1.12 (71.5 + 8.4 mmHg) 10.29 + 1.28 (77.2 + 9.6 mmHg) <0.002 Albumin (g/L) 42.9 + 2.6 40.0 + 3.0 NS ALT (U/l) 38.6 + 11.8 44.9 + 19.5 NS AST (U/l) 17.8 + 5.5 20.0 + 8.6 NS GGT (U/l) 24.3 + 8.9 33.6 + 16.4 <0.001 ALP (U/l) 73.96 + 20.83 85.79 + 18.84 <0.004 HOMA-IR 2.09 + 1.4 3.86 + 1.9 <0.0001 Insulin (pmol/L) 56 + 35 (9.35 + 5.85 µU/ml) 98 + 44 (16.36 + 7.32 µU/ml) <0.0001 Fasting glucose (mmol/L) 4.9 + 0.3 (89.3 + 6.3 mg/dl) 5.2 + 0.6 (94.5 + 10.6 mg/dl) <0.005 Total cholesterol (mmol/L) 4.40 + 0.73 (170.0 + 28.2 mg/dl) 4.76 + 0.84 (184.2 + 32.5 mg/dl) <0.023 Triglyceride (mmol/L) 0.82 + 0.41 (72.9 + 36.2 mg/dl) 1.15 + 0.59 (101.6 + 52.6 mg/dl) <0.002 HDL-Cholesterol (mmol/L) 1.47 + 0.40 (56.9 + 15.6 mg/dl) 1.29 + 0.33 (50.0 + 12.8 mg/dl) <0.02 Values are means + SD; NS = not significant. Legend: BP s= Blood pressure; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; GGT = Gamma glutamyl transpeptidase; ALP = alkaline phosphatase; HOMA IR = homeostasis model assessment of insulin resistance; HDL = High Density Lipoprotein A L I I B R A H I M A L -S U LTA N 188 measured. Results are presented as mean + standard deviation. R E S U L T S The clinical and biochemical characteristics of study subjects are shown in Table 1. The obese subjects were significantly older than non-obese (p<0.0001). Obese individuals had a mean age 28.8 + 6.9 years with a median 27.00 and a minimum and maximum age of 19 and 47 respectively. Non-obese individuals had a mean age 24.6 + 3.7 years with a median 24.00 and a minimum and maximum age of 20 and 41 respec- tively. Obese subjects had higher BMI, waist-to-hip ratio (WHR), systolic and diastolic blood pressure ( p< 0.0001, <0.0001, < 0.007 and <0.002 respectively). The means of serum albumin levels were lower, and ALT and AST levels were higher in obese individuals, but there was no significant statistical difference. The obese subjects had significantly higher GGT, and ALP levels (p < 0.001 and 0.004 respectively). Obese indi- viduals had significantly higher fasting blood glucose, (p < 0.005). HOMA IR scores, and insulin were sig- nificantly higher in obese subjects (p <0.0001). Total cholesterol, triglycerides, and HDL- cholesterol were significantly higher in obese individuals (p <0.023, <0.002, and <0.02 respectively). Table 2 shows correlations of liver function tests with clinical and biochemical variables. All hepatic enzymes (ALT, AST, GGT, and ALP) were associated with measures of obesity including BMI, and WHR, but GGT had the strongest correlations with r 0.339, r 0.509 respectively, (p < 0.01). Figure 1 shows the line graph of the correlation of ALT, AST, and GGT with BMI. Serum albumin was inversely associated with BMI r - 0.426, (p < 0.01). Systolic blood pressure cor- related significantly with ALT, AST, GGT, and ALP, (p <0.01, <0.01, <0.01, and <0.01 respectively). Diastolic blood pressure correlated significantly with ALP, (p <0.05). ALT, AST, and GGT correlated with measures of insulin resistance including HOMA IR, insulin, and fasting glucose. GGT had the strongest correlations with HOMA IR, and insulin r 0.481, r 0.476, respec- tively (p < 0.01). Figure 2 shows the line graph of the Serum Albumin (g/dl) ALT (U/l) AST (U/l) GGT (U/l) ALP (U/l) Body mass index - 0.426 ** 0.263 ** 0.320 ** 0.339 ** 0.290** Waist to hip ratio - 0.041 0.302 ** 0.313 ** 0.509 ** 0.145 Systolic blood pressure 0.117 0.263 ** 0.313 ** 0.369 ** 0.273** Diastolic blood pressure - 0.055 0.085 0.000 0.189 0.257* HOMA-IR - 0.251 * 0.462 ** 0.354 ** 0.481 ** 0.143 Insulin - 0.279 ** 0.414 ** 0.318 ** 0.476 ** 0.146 Fasting glucose - 0.053 0.280 ** 0.278 ** 0.230 * 0.132 Total Cholesterol - 0.039 0.204 * 0.150 0.295 ** 0.228* Triglyceride - 0.144 0.314 ** 0.206 * 0.493 ** 0.189 HDL-Cholesterol 0.047 - 0.311 ** - 0.285 ** - 0.365 ** - 0.118 * p < 0.05 and ** p value < 0.01 Legend: ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; GGT = Gamma glutamyl transpeptidase; ALP = alkaline phosphatase; HOMA IR = homeostasis model assessment of insulin resistance; HDL = High Density Lipoprotein Table 2: Correlations of hepatic enzymes and serum albumin with the clinical and biochemical param- eters of all 136 study subjects. A S S E S S M E N T O F T H E R E L AT I O N S H I P B E T W E E N H E PAT I C E N Z Y M E S W I T H O B E S I T Y A N D I N S U L I N R E S I S TA N C E I N A D U LT S I N S AU D I A R A B I A 189 correlation of ALT, AST, and GGT with HOMA IR. ALT, GGT, and ALP correlated with total cholesterol. ALT, AST, and GGT correlated with triglycerides, and inversely with HDL-cholesterol. Serum albumin had significant negative correlation with HOMA IR, and insulin r - 0.251, r - 0.279 (p < 0.05 and <0.01 respec- tively). D I S C U S S I O N GGT and ALP were significantly higher in obese than non-obese subjects, while ALT and AST did not show a significant difference. ALT, AST, and GGT cor- related significantly with BMI. A similar significant correlation was found with WHR and systolic blood pressure. HOMA-IR and serum insulin correlated sig- nificantly with ALT, AST, and GGT. In various studies, aminotransferases, especially ALT, have been shown to correlate with obesity,7-11, 27 and insulin resistance.7, 9, 12, 16, 27, 28 Among hepatic enzymes, ALT is the most spe- cific indicator of hepatic pathology in non-alcoholic fatty liver disease. GGT is considered to be a sensitive marker of hepatic damage, but it is not specific espe- cially in societies with abundance of alcohol intake. In this study, GGT had the strongest correlations for BMI r 0.339, WHR r 0.509, systolic blood pressure r 0.369, insulin levels r 0.476, and HOMA IR r 0.481, compared to other liver enzymes. In addition, GGT correlated significantly with fasting glucose, total cho- lesterol, triglycerides, and inversely with HDL-choles- terol, r 0.230, r 0.295, r 0.493, r 0.365 (p <0.05, <0.01, <0.01, and <0.01 respectively). Previous studies have shown positive correlation between GGT and meas- ures of obesity and insulin resistance,2, 5, 6, 10, 13, 24, 30 and to predict diabetes mellitus.19-23 It is also reported to be increased in patients with ischaemic heart disease.5 The findings of this study and the literature suggest a major role of GGT in the manifestation of liver pathol- ogy associated with obesity and insulin resistance. In this study, ALP correlated significantly with BMI, systolic and diastolic blood pressure, and to- Figure 1: Correlation of alanine aminotrans- ferase (ALT), aspartate aminotransferas (AST), and gamma glutamyl transpeptidase (GGT) with body mass index Figure 2: Correlation of alanine aminotransfer- ase (ALT), Aspartate aminotransferase (AST), and gamma glutamyl transpeptidase (GGT) with homeostasis model assessment of insulin resis- tance (HOMA IR). A L I I B R A H I M A L -S U LTA N 190 tal cholesterol. It had been reported to be higher in obese than non-obese subjects as has been observed in this study,3, 31, 32 without significant correlation with HOMA-IR. Serum albumin showed significant inverse cor- relation with BMI, HOMA IR, and serum insulin. It has been reported that glycated albumin is associat- ed negatively with obesity in non-diabetic children,25 and more recently in non-diabetic adults.33 Glycated albumin is lower in obese diabetics,34 and correlates negatively with body mass index.35 The etiology of this observation is not yet known. In this study, a nega- tive association between serum albumin and obesity was found. Serum albumin level reflects the rate of synthesis, degradation, and volume of distribution. In- crease vasopermeability is suggested by literature re- ports of increase in albumin extravasation in skeletal muscles in the obese Zucker rat model, 36 and as well by an increase in transcapillary escape rate of albumin in hypertensive patients with metabolic syndrome.37 Endothelial dysfunction had been reported to be re- lated to elevated ALT levels among patients with dia- betes mellitus.38 Although microalbuminuria was not present in the study subjects as per inclusion criteria, it is another potential explanation and mechanism for the observed relationship of albumin and obesity. Microalbuminuria is an established marker of cardio- vascular disease and reflects vascular dysfunction as a manifestation of a proposed low grade inflammation associated with obesity and insulin resistance.39 Obes- ity is an independent risk for microalbuminuria,40, 41 with the risk being parallel to changes in weight.42 C O N C L U S I O N In conclusion, ALT, AST, and GGT correlated with measures of obesity, and HOMA-IR. GGT had the strongest correlations and might be a better marker of hepatic pathology associated with obesity, and insulin resistance in Saudi and other subjects with no alcohol intake. Serum albumin correlated inversely with BMI and HOMA-IR suggesting an altered metabolism or handling of albumin in obesity. A C K N OW L E D GE ME N TS The research was performed at the Colleges of Medi- cine in Al-Ahsa and Dammam, at King Faisal Univer- sity, Saudi Arabia. It was conducted during 2004-2005. It was funded by the Deanship of Research and the College of Medicine in Al-Ahsa, at King Faisal Uni- versity. The author would like to thank Dr. Abdulmohsin Al-Elq, Professor Prem Nath Dogra, Professor Sha- hid Baig, and Professor Amro Heshmat Rustem at the Departments of Internal Medicine, Surgery, and Bio- medical Sciences at King Faisal University, Carmen Lizardo, Jacqueline Manaois, Purita Cabinian, and Issa Jebreel from the laboratories of King Fahd Hospital of the University, for collection of data, review of manu- script and technical help. R E F E R E N C E S 1. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and fer- ritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004; 28:167-172. 2. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall’Aglio E, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are as- sociated with insulin resistance and the metabolic syn- drome. J Endocrinol Invest 2005; 28:333-339. 3. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes 1984; 8:107-115. 4. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 1998; 22:222-226. 5. Wannamethee G, Ebrahim S, Shaper AG. Gamma- glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142:699-708. 6. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Re- unanen A, Kesäniemi YA. Gamma-glutamyl transpepti- dase and the metabolic syndrome. J Intern Med 2000; 248:230-238. 7. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotrans- ferase activity in the United States. Gastroenterology 2003; 124:71-79. 8. Sattar N, Scherbakova O, Ford I, O’Reilly DS, Stanley A, Forrest E, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reac- tive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53:2855-2860. 9. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin re- sistance atherosclerosis study. Diabetes 2004; 53:2623- 2632. 10. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the A S S E S S M E N T O F T H E R E L AT I O N S H I P B E T W E E N H E PAT I C E N Z Y M E S W I T H O B E S I T Y A N D I N S U L I N R E S I S TA N C E I N A D U LT S I N S AU D I A R A B I A 191 risk of type 2 diabetes in older men. Diabetes Care 2005; 28:2913-2918. 11. West J, Brousil J, Gazis A, Jackson L, Mansell P, Ben- nett A , et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 2006; 9:871-876. 12. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is as- sociated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51:1889-1895. 13. Choi JW. Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Ann Clin Lab Sci 2003; 33:257-264. 14. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum alanine aminotransferase is associated with serum adi- ponectin, C-reactive protein and apolipoprotein B in young healthy men. Horm Metab Res 2006; 38:119- 124. 15. Ardigo D, Numeroso F, Valtuena S, Franzini L, Piatti PM, Monti L, et al. Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transami- nase concentrations. Metabolism 2005; 54:1566-1570. 16- Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, et al. The association between increased alanine ami- notransferase activity and metabolic factors in nonal- coholic fatty liver disease. Metabolism 2006; 55:1604- 1609. 17. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and de- velopment of the metabolic syndrome: the insulin re- sistance atherosclerosis study. Diabetes 2005; 54:3140- 3147. 18. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005; 329:111-116. 19. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21:732-737. 20. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predic- tor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003; 49:1358-1366. 21. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and dia- betes - a 4 year follow-up study. Diabetologia 2003; 46:359-364. 22. Nakanishi N, Suzuki K, Tatara K. Serum gamma- glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Dia- betes Care 2004; 27:1427-1432. 23. Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomi- leto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin En- docrinol Metab 2004; 89:5410-5414. 24. Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Se- rum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006; 91:1419- 1422. 25. Nishimura R, Kanda A, Sano H, Matsudaira T, Miya- shita Y, Morimoto A, et al. Glycated albumin is low in obese, non-diabetic children. Diabetes Res Clin Pract 2006; 71:334-338. 26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess- ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. 27. Hanley AJ, Wagenknecht LE, Festa A, D’Agostino RB Jr, Haffner SM.Alanine Aminotransferase (ALT) and Directly Measured Insulin Sensitivity in a Multi-ethnic Cohort. The Insulin Resistance Atherosclerosis Study. Diabetes Care 2007; 30:1819-1827. 28. Sung KC, Ryan MC, Kim BS, Cho YK, Kim BI, Reaven GM. Relationships Between Estimates of Adiposity, In- sulin Resistance and Nonalcoholic Fatty Liver Disease in a Large Group of Nondiabetic Korean Adults. Diabe- tes Care 2007; 30:2113-2118. 29. Wannamethee G, Ebrahim S, Shaper AG. Gamma- glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142:699-708. 30. Yokoyama H, Hirose H, Moriya S, Saito I. Significant correlation between insulin resistance and serum gam- ma glutamyl transpeptidase (gamma-GTP) activity in non-drinkers. Alcohol Clin Exp Res 2002; 26:91S-94S. 31. Ali AT, Paiker JE, Crowther NJ. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin. Am J Clin Pathol 2006; 126:437-442. 32. Liu M, Yan HM, Gao X, Gao J. Association of abnormal- ity of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease. Zhonghua Yi Xue Za Zhi 2007; 87:253-255. 33. Koga M, Otsuki M, Matsumoto S, Saito H, Mukai M, Kasayama S. Negative association of obesity and its related chronic inflammation with serum glycated al- bumin but not glycated hemoglobin levels. Clin Chim Acta 2007; 378:48-52. 34. Miyashita Y, Nishimura R, Morimoto A, Matsudaira T, Sano H, Tajima N. Glycated albumin is low in obese, type 2 diabetic patients. Diabetes Res Clin Pract 2007; 78:51-55. A L I I B R A H I M A L -S U LTA N 192 35. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 2006; 53:387-391. 36. St-Pierre P, Bouffard L, Papirakis ME, Maheux P. In- creased extravasation of macromolecules in skeletal muscles of the Zucker rat model. Obesity (Silver Spring) 2006; 14:787-793. 37. Dell’Omo G, Penno G, Pucci L, Mariani M, Del Prato S, Pedrinelli R.Abnormal capillary permeability and en- dothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis 2004; 172:383- 389. 38. Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T, et al. Liver alanine aminotrans- ferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005; 35:369-374. 39. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens 2007; 9:196-200. 40. Chandie Shaw PK, Berger SP, Mallat M, Frolich M, Dekker FW, Rabelink TJ. Central obesity is an independ- ent risk factor for albuminuria in “non-diabetic” South Asian subjects. Diabetes Care 2007; 30:1840-1844. 41. Hao Z, Konta T, Takasaki S, Abiko H, Ishikawa M, Taka- hashi T, et al. The association between microalbuminu- ria and metabolic syndrome in the general population in Japan: the Takahata study. Intern Med 2007; 46:341- 346. 42. Bello AK, de Zeeuw D, Nahas ME, Brantsma AH, Bakker SJ, de Jong PE, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007; 22:1619-1627.